Gianluca Mauri

Education Nov 2020 – today PhD Student in Molecular Oncology, European School of Molecular Medicine (SEMM), IFOM-FIRC Institute of Molecular Oncology, Università degli Studi di Milano, Milano (Italy) Sept 2021 European Society of Medical Oncology (ESMO) Examination Certificate (Milan, Sept 18th, 2021) Nov 2016 – Nov 2021 Graduation in Medical Oncology, Università degli Studi di Milano, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda Milano (Italy) Final mark: 70 e lode (Full marks with honors) Thesis: Circulating tumor DNA analysis unveils mechanisms of resistance to anti-EGFR rechallenge in metastatic colorectal cancer: translational results from the CHRONOS phase II trial February 2016 Italian Certificate of Medical Licensure Oct 2009 - July 2015 Graduation in Medicine, Università di Milano-Bicocca, Milano (Italy) Additional courses in: \"Colorectal cancer: multidisciplinary approach\", \"Breast cancer: multidisciplinary approach\", \"Lung cancer: multidisciplinary approach\", \"Digestive oncology\", \"Focal liver lesions\", \"Medical statistics for clinical research\". Final mark: 110 e lode (Full marks with honors) Thesis: Liquid biopsy for tailoring treatment and tracking resistance to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 2004 – 2009 Liceo scientifico \"Galileo Galilei \", Erba - Como (Italy) Final grade: 100/100 (Full marks) Internship and scholarship Oct 2015 - Oct 2016 Postgraduate scholarship at Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano (Italy) Title: \"Gene fusions as therapeutic targets in gastrointestinal malignancies\". Oct 2013 - Sept 2015 Niguarda Cancer Centre, ASST Grande Ospedale Metropolitano Niguarda, Milano (Italy) Clinical and research activities focused on gastrointestinal cancers and mechanisms of resistance to targeted therapies (Mentor: Associate Professor Andrea Sartore-Bianchi). July - Sept 2014 Summer internship in the Laboratory of Experimental Molecular Clinical Oncology, IRCCS Institute of Candiolo, Torino (Italy) Research activities with special regard to molecular mechanisms of acquired resistance to anti-EGFR treatment in colorectal cancer (Director: Professor Alberto Bardelli). Jan - June 2013 Internship in Medical Oncology, \"A. Manzoni\" Hospital, Lecco (Italy) Clinical activities with special regard to breast and gynecologic cancers. International Scholarship Jan – June 2019 Massachusetts General Hospital, Harvard Medical School, Boston – MA (USA) Research fellow. Translational research in the field of gastrointestinal malignancies with particular regard to early-onset timing, MAPK pathway and DNA Damage Repair (DDR) alterations in colorectal cancer (Mentor: Associate Professor Ryan B. Corcoran). July - Sept 2013 Segal Cancer Centre, Jewish General Hospital, Montreal (Canada) Clinical and research activities with special regard to breast cancer and genitourinary cancers (Mentor: Dr. Cristiano Ferrario). Honors and awards June 2018 Ermenegildo Zegna Founder’s Scholarship 2018-2019 holder. May 2020 Selected for the EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research Virtual Workshop 2020. June 2020 Winner of the \"Young Oncologists for mCRC, a clinical challenge\" organized by Sanofi Genzyme. June 2021 Invited speaker at the 32° Virtual Pezcoller Conference on “Aging and cancer” providing a lecture entitled “The emerging challenge of early-onset colorectal cancer”. August 2021 Selected for the EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research Workshop 2021 scheduled from 18 to 24 June 2022 in De Ruwenberg in Sint-Michielsgestel, Netherlands. Key skills Languages Proficient in English: IELTS score 8.0 corresponding to a CEFR Level of C1 (April 2019). Basic spoken French. IT skills Basic use of computer according to the program of the European Computer Driving License (ECDL) achieved in 2009. Peer Reviewed Scientific Publications 1. Bencardino K, Mauri G*, Amatu A, Tosi F, Bonazzina E, Palmeri L, Querques M, Ravera F, Menegotto A, Boiani E, Sartore-Bianchi A, Siena S. Oxaliplatin ImmuneInduced Syndrome Occurs with Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clin Colorectal Cancer. 2016 Sep;15(3):213-21. doi: 10.1016/j.clcc.2016.02.001. Epub 2016 Feb 19. *equally contributed as first author. 2. Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, Sartore-Bianchi A, Siena S. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and MetaAnalysis. Clin Colorectal Cancer. 2017 Sep;16(3):e153-e163. doi:10.1016/j.clcc.2017.01.004. Epub 2017 Jan 25. 3. Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 Mar;17(1):80-83. doi: 10.1016/j.clcc.2017.10.017. Epub 2017 Nov 1. 4. Mauri G, Valtorta E*, Cerea G, Amatu A, Schirru M, Marrapese G, Fiorillo V, Recchimuzzo P, Cavenago IS, Bonazzina EF, Motta V, Lauricella C, Veronese S, Tosi F, Maiolani M, Rospo G, Truini M, Bonoldi E, Christiansen J, Potts SJ, Siena S, Sartore-Bianchi A. TRKA expression and NTRK1 gene copy number across solid tumours. J Clin Pathol. 2018 Oct;71(10):926- 931. doi: 10.1136/jclinpath-2018-205124. Epub 2018 May 25. *equally contributed as first author. 5. Mauri G, Bencardino K, Sartore-Bianchi A, Siena S. Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. Ann Oncol. 2018 Oct 1;29(10):2143-2144. doi: 10.1093/annonc/mdy306. 6. Mauri G, Sartore-Bianchi A*, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019 Feb;13(2):109-131. doi: 10.1002/1878-0261.12417. Epub 2018 Dec 22. Review. *equally contributed as first author. 7. Mauri G, Pizzutilo EG*, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27. *equally contributed as first author. 8. Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, Greco L, Pitrone C, Valtorta E, Mauri G, Truini M, Dall'Olio FG, Brandi G, Sartore-Bianchi A, Ricciardiello L, Torri V, Rimassa L, Siena S, Mantovani A, Malesci A, Laghi L. Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression. Cancer Immunol Res. 2019 Feb 25. pii: canimm.0661.2018. doi: 10.1158/2326-6066.CIR-18-0661. [Epub ahead of print]. 9. Russo AG, Andreano A, Sartore-Bianchi A, Mauri G, Decarli A, Siena S. Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. Cancer Epidemiol. 2019 Apr 18;60:134- 140. doi: 10.1016/j.canep.2019.03.015. [Epub ahead of print]. 10. Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella C, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, Abrignani S, Siena S, Di Nicolantonio F, Bardelli A. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clin Cancer Res. 2020 Mar 15;26(6):1372- 1384. doi: 10.1158/1078-0432.CCR-19-2409. Epub 2019 Dec 12. 11. Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A. The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020. Epub 2020 Jun 5. 12. Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, Martino C, Bencardino K, Bonazzina E, Bergamo F, Fenocchio E, Martinelli E, Troiani T, Siravegna G, Mauri G, Torri V, Marrapese G, Valtorta E, Cassingena A, Cappello G, Bonoldi E, Vanzulli A, Regge D, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Marsoni S, Siena S. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer, 2020. (Online ahead of print). 13. Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev. 2020 (Online ahead of print). 14. Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer. Cancers (Basel). 2021 Jan 4;13(1):E137. doi: 10.3390/cancers13010137. 15. Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Target Oncol. 2021 Mar 18. doi: 10.1007/s11523-021-00795-5. Online ahead of print. 16. Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open. 2021 May 24;6(3):100156. doi: 10.1016/j.esmoop.2021.100156. Online ahead of print. 17. Kanter K, Fish M*, Mauri G*, Horick NK, Allen JN, Blaszkowsky LS, Clark JW, Ryan DP, Nipp RD, Giantonio BJ, Goyal L, Dubois J, Murphy JE, Franses J, Klempner SJ, Roeland EJ, Weekes CD, Wo JY, Hong TS, Van Seventer EE, Corcoran RB, Parikh AR. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncol Pract. 2021 May 27;OP2001010. doi: 10.1200/OP.20.01010. Online ahead of print. *equally contributed as first author. 18. Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers 2021, 13(11), 2638; https://doi.org/10.3390/cancers13112638 - 27 May 2021. 19. Mauri G, Durinikova E, Amatu A, Tosi F, Cassingena A, Rizzetto F, Buzo K, Arcella P, Aquilano MC, Bonoldi E, Marsoni S, Siena S, Bardelli A, Sartore-Bianchi A, Arena S. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precis Oncol. 2021 Jul 21;5:PO.21.00143. doi: 10.1200/PO.21.00143. eCollection 2021 Jul. 20. Patelli G, Bencardino K, Tosi F, Pugliano M, Lanzani F, Innocenti A, Rinaldo A, Mauri G, Cerea G, Sartore-Bianchi A, Torre M, Agostoni EC, Siena S. Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature. J Med Case Rep. 2021 Feb 2;15(1):32. doi: 10.1186/s13256-020-02601-8. 21. Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S, Siena S, Bardelli A. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer. 2022 Mar 9. doi: 10.1038/s41416-022-01769-8. Online ahead of print. 22. Amatu A, Mauri G*, Tosi F, Bencardino K, Bonazzina E, Gori V, Ruggieri L, Arena S, Bardelli A, Marsoni S, Siena S, Sartore-Bianchi A. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers (Basel). 2022 Feb 25;14(5):1197. doi: 10.3390/cancers14051197. *Equally contributed as first author. 23. Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, Morano F, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Alberto Bardelli. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 2022 May 6;candisc.1434.2021. doi: 10.1158/2159-8290.CD-21-1434. Online ahead of print. 24. Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, Cremolini C. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. 2022 Jun 3. doi: 10.1038/s41416-022-01852-0. Online ahead of print. 25. Sartore-Bianchi A, Agostara AG, Patelli G, Mauri G, Pizzutilo EG, Siena S. Application of histology-agnostic treatments in metastatic colorectal cancer. Dig Liver Dis. 2022 Jun 11:S1590-8658(22)00512-6. doi: 10.1016/j.dld.2022.05.013. Online ahead of print. 26. Durinikova E, Reilly NM, Buzo K, Mariella E, Chilà R, Lorenzato A, Dias JML, Grasso G, Pisati F, Lamba S, Corti G, Degasperi A, Cancelliere C, Mauri G, Andrei P, Linnebacher M, Marsoni S, Siena S, Sartore-Bianchi A, Nik-Zainal S, Di Nicolantonio F, Bardelli A, Arena S. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clin Cancer Res. 2022 Jul 26:OF1-OF16. doi: 10.1158/1078-0432.CCR-22-0875. Online ahead of print. 27. Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug 1. doi: 10.1038/s41591- 022-01886-0. Online ahead of print.